Cite
MLA Citation
Karthikeyan Pethusamy et al.. “Loss of TET2 with reduced genomic 5-hmC is associated with adverse-risk AML.” Leukemia & lymphoma, vol. 63, no. 14, 2022, pp. 3426–3432. http://access.bl.uk/ark:/81055/vdc_100174903625.0x00003f
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Karthikeyan Pethusamy et al.. “Loss of TET2 with reduced genomic 5-hmC is associated with adverse-risk AML.” Leukemia & lymphoma, vol. 63, no. 14, 2022, pp. 3426–3432. http://access.bl.uk/ark:/81055/vdc_100174903625.0x00003f